X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES TORRENT PHARMA VENUS REMEDIES/
TORRENT PHARMA
 
P/E (TTM) x -930.4 25.8 - View Chart
P/BV x 0.3 6.3 4.3% View Chart
Dividend Yield % 0.0 3.2 -  

Financials

 VENUS REMEDIES   TORRENT PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
TORRENT PHARMA
Mar-16
VENUS REMEDIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs2181,720 12.7%   
Low Rs821,134 7.2%   
Sales per share (Unadj.) Rs365.6394.5 92.7%  
Earnings per share (Unadj.) Rs1.5101.8 1.5%  
Cash flow per share (Unadj.) Rs37.9116.3 32.6%  
Dividends per share (Unadj.) Rs040.00 0.0%  
Dividend yield (eoy) %02.8 0.0%  
Book value per share (Unadj.) Rs382.5200.3 191.0%  
Shares outstanding (eoy) m11.44169.22 6.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.6 11.3%   
Avg P/E ratio x101.014.0 720.3%  
P/CF ratio (eoy) x4.012.3 32.3%  
Price / Book Value ratio x0.47.1 5.5%  
Dividend payout %039.3 0.0%   
Avg Mkt Cap Rs m1,717241,435 0.7%   
No. of employees `0001.010.9 9.4%   
Total wages/salary Rs m3248,559 3.8%   
Avg. sales/employee Rs Th4,100.76,129.6 66.9%   
Avg. wages/employee Rs Th318.0785.8 40.5%   
Avg. net profit/employee Rs Th16.71,581.3 1.1%   
INCOME DATA
Net Sales Rs m4,18366,764 6.3%  
Other income Rs m202,156 0.9%   
Total revenues Rs m4,20368,920 6.1%   
Gross profit Rs m81227,204 3.0%  
Depreciation Rs m4172,461 16.9%   
Interest Rs m3801,859 20.4%   
Profit before tax Rs m3525,041 0.1%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-1,403 0.0%   
Tax Rs m186,414 0.3%   
Profit after tax Rs m1717,224 0.1%  
Gross profit margin %19.440.7 47.6%  
Effective tax rate %51.625.6 201.3%   
Net profit margin %0.425.8 1.6%  
BALANCE SHEET DATA
Current assets Rs m2,77146,622 5.9%   
Current liabilities Rs m1,93132,843 5.9%   
Net working cap to sales %20.120.6 97.2%  
Current ratio x1.41.4 101.1%  
Inventory Days Days12574 168.4%  
Debtors Days Days5479 68.0%  
Net fixed assets Rs m5,32839,029 13.7%   
Share capital Rs m114846 13.5%   
"Free" reserves Rs m4,17731,400 13.3%   
Net worth Rs m4,37633,890 12.9%   
Long term debt Rs m1,91118,637 10.3%   
Total assets Rs m8,42890,136 9.4%  
Interest coverage x1.114.5 7.5%   
Debt to equity ratio x0.40.5 79.4%  
Sales to assets ratio x0.50.7 67.0%   
Return on assets %4.721.2 22.2%  
Return on equity %0.450.8 0.8%  
Return on capital %6.648.5 13.6%  
Exports to sales %043.3 0.0%   
Imports to sales %20.56.9 298.9%   
Exports (fob) Rs mNA28,934 0.0%   
Imports (cif) Rs m8584,584 18.7%   
Fx inflow Rs m029,185 0.0%   
Fx outflow Rs m8586,021 14.3%   
Net fx Rs m-85823,165 -3.7%   
CASH FLOW
From Operations Rs m46927,132 1.7%  
From Investments Rs m29-7,014 -0.4%  
From Financial Activity Rs m-464-14,352 3.2%  
Net Cashflow Rs m355,767 0.6%  

Share Holding

Indian Promoters % 32.9 71.5 45.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 7.0 2.6%  
FIIs % 0.6 12.6 4.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 8.8 754.5%  
Shareholders   20,121 26,511 75.9%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  GSK PHARMA  PLETHICO PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 22, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ALEMBIC PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS